Skip to main content

Market Overview

AzurRx BioPharma Stock Gains On Positive MS1819-PERT Combo Data In Pancreatic Insufficiency

AzurRx BioPharma Stock Gains On Positive MS1819-PERT Combo Data In Pancreatic Insufficiency
  • AzurRx BioPharma Inc (NASDAQ: AZRXannounced positive interim data from the first 18 out of 20 patients from its Phase 2 trial. The study was evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT), for severe exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).
  • The interim data revealed that the combination therapy led to clinically meaningful improvements in the primary efficacy endpoint, the Coefficient of Fat Absorption (CFA), with an average gain of 5.9 points from baseline, over the six-week trial.
  • "It is also very encouraging to note that all the patients responded well and that many reported that they felt better overall when MS1819 was added to their daily dose of PERT", said Dr. James Pennington, Chief Medical Officer. 
  • Full topline results from all 20 patients enrolled in the trial are expected in the second quarter of 2021.
  • MS1819 is a recombinant lipase enzyme supplied as an oral, non-systemic, biologic capsule derived from the Yarrowia lipolytica yeast lipase.
  • It breaks up fat molecules in the digestive tract of EPI patients to be absorbed as nutrients.
  • Price Action: AZRX shares are trading 8.9% higher at $0.79 during the premarket session on the last check Thursday.

Related Articles (AZRX)

View Comments and Join the Discussion!

Posted-In: Briefs Cystic Fibrosis Pancreatic CancerBiotech News Penny Stocks Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at